| __timestamp | Ascendis Pharma A/S | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 3852327 |
| Thursday, January 1, 2015 | 9415000 | 839656 |
| Friday, January 1, 2016 | 11504000 | 4478145 |
| Sunday, January 1, 2017 | 13482000 | 16432324 |
| Monday, January 1, 2018 | 25057000 | 11890871 |
| Tuesday, January 1, 2019 | 48473000 | 34110000 |
| Wednesday, January 1, 2020 | 76669000 | 35781000 |
| Friday, January 1, 2021 | 160180000 | 40896000 |
| Saturday, January 1, 2022 | 221227000 | 52200000 |
| Sunday, January 1, 2023 | 264410000 | 59836000 |
Unleashing the power of data
In the competitive landscape of biopharmaceuticals, understanding financial trends is crucial. Over the past decade, Ascendis Pharma A/S and Merus N.V. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Ascendis Pharma A/S has seen a dramatic increase, with expenses rising by over 4,100% from 2014 to 2023. This surge reflects their aggressive expansion and investment in operational capabilities. In contrast, Merus N.V. has experienced a more modest growth of approximately 1,500% in the same period, indicating a more conservative approach. By 2023, Ascendis Pharma's SG&A expenses were nearly 4.5 times higher than those of Merus N.V., highlighting their differing strategies in scaling operations. These trends offer a window into the strategic priorities of these companies as they navigate the evolving pharmaceutical market.
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Merus N.V.
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Merus N.V.: SG&A Expense Trends
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated
Who Optimizes SG&A Costs Better? Merus N.V. or Amphastar Pharmaceuticals, Inc.